|Bid||0.00 x 36200|
|Ask||0.00 x 28000|
|Day's Range||7.74 - 7.90|
|52 Week Range||5.89 - 12.20|
|Beta (5Y Monthly)||1.31|
|PE Ratio (TTM)||5.37|
|Forward Dividend & Yield||0.31 (4.11%)|
|Ex-Dividend Date||Aug 11, 2022|
|1y Target Est||N/A|
Barclays Chief Executive C.S. Venkatakrishnan said on Tuesday that his cancer was detected early and is "very localised", meaning that doctors are very optimistic about treating it. The British bank said on Monday that Venkatakrishnan would undergo treatment in New York for non-Hodgkin lymphoma. Barclays has not appointed an interim replacement and said the CEO will stay involved with running it where treatment allows.
Dismal investment banking performance and rising provisions are expected to have hurt Toronto-Dominion's (TD) fiscal Q4 earnings, while higher interest rates and improved trading might have aided.
Investors need to pay close attention to Barclays (BCS) stock based on the movements in the options market lately.